NuCana (NASDAQ:NCNA) Issues Quarterly Earnings Results, Beats Estimates By $1.66 EPS

NuCana (NASDAQ:NCNA) posted its quarterly earnings data on Thursday. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.65) by $1.66, Zacks reports.

NuCana Stock Performance

NCNA stock traded up $0.15 on Friday, hitting $1.63. 42,356 shares of the company’s stock were exchanged, compared to its average volume of 51,743. The stock has a market cap of $6.78 million, a P/E ratio of -0.55 and a beta of 2.25. The firm has a 50 day moving average price of $1.52 and a two-hundred day moving average price of $1.87. NuCana has a 12-month low of $1.21 and a 12-month high of $7.22.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.